6 articles in this category
Surging ANKTIVA sales and FDA clearance path signal strong near-term upside despite negative margins.
Negative free cash flow contrasts with explosive 700% revenue growth and FDA progress, triggering strong near-term upside potential.
Negative free cash flow offset by $1.25B cash runway and FDA alignment on BEAM-302; catalyst-driven rally likely in coming weeks.
Strong cash runway and upcoming ASH data catalyst for BEAM-101 drive near-term upside potential despite negative free cash flow.
Strong free cash flow and deep pipeline momentum signal upside, with near-term Phase 3 readouts acting as catalysts for stock re-rating.
Despite deteriorating revenue trends, upcoming clinical data readout and strong cash runway provide near-term catalysts for stock appreciation.